All In Biotech

Drug Trial Radar · NCT06821945

A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia

A Multi-Center, Randomized, Double-Blind, Parallel-Design, Exploratory Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia

Last checked: Nov 19, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

May 30, 2025

Primary completion

May 2027

Study completion May 2027

Sponsor

Sponsor type
Industry
First posted
Feb 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this clinical trial is to evaluate the safety and efficacy of olanzapine titration schedule in patients with schizophrenia

Conditions

  • Schizophrenia

Interventions

  • BR5402ADrug

    Subjects take the investigational products once a day

  • BR5402A-1Drug

    Subjects take the investigational products once a day

  • BR5402BDrug

    Subjects take the investigational products once a day

  • BR5402B-1Drug

    Subjects take the investigational products once a day

  • BR5402CDrug

    Subjects take the investigational products once a day

  • BR5402C-1Drug

    Subjects take the investigational products once a day

  • BR5402DDrug

    Subjects take the investigational products once a day

  • BR5402D-1Drug

    Subjects take the investigational products once a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The mean change of PANSS(Positive and Negative Syndrome Scale) total scoreTime frame: 1, 2, 3, 5, 9 weeks from baseline(Visit 2)
  2. Incidence of treatment-emergent adverse eventsTime frame: From the administration of investigational products prescribed at baseline(Visit 2) to 11 weeks(Visit 8)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Kyungbook National university hospital

    Daegu, South Korea · Recruiting

  • Hanyang University Guri Hospital

    Guri-si, South Korea · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.